BXMT heads into the back half of the week with two things happening simultaneously: short sellers bailing out at a pace rarely seen in the stock, and the Street's most closely watched analyst turning outright bullish.
The short interest story is the sharpest signal this week. The float on loan collapsed from roughly 7% of free float in mid-April to 4.8% now — a drop of more than 30% in a single week and the lowest reading in at least six weeks. That unwind is abrupt. SI was running above 7% as recently as April 15th before a sharp flush on April 23rd cut it by almost two percentage points in a single session. The borrow market reflects the exit: cost to borrow is a negligible 0.48%, down 22% versus a month ago. Availability is loose throughout the lending pool, consistent with a stock where there is no structural scarcity of shares to borrow. The ORTEX short score, which hit a local high of 56.3 on April 17th, has dropped to 45.9 — a meaningful decompression that tracks almost exactly with the SI unwind.
Options positioning tells a different, more cautious tale. The put/call ratio has fallen to 1.81 — actually its lowest level of the past year — sitting more than a standard deviation below the 20-day average of 1.94. That sounds bullish on the surface, but the absolute PCR level is still elevated, well above 1.0, meaning puts continue to dominate significantly. The move lower is less a sign of new bullishness and more a moderation of the heavy defensive overhang that had been building since March, when the PCR ran above 2.1. The structural hedging in BXMT's options market has simply gotten a little less intense.
The most significant Street development this month was JP Morgan's Richard Shane upgrading BXMT to Overweight from Neutral on April 16th, setting a $21 price target. That reverses a stance Shane had held through most of late 2025, during which he was gradually nudging his Neutral target higher from $18.50 to $20. The upgrade lands at a moment when the stock has already recovered — BXMT is up 6% over the past month to $20.01, and now trades essentially at book value (P/B of 1.0). Other active coverage remains constructive: Keefe Bruyette held Outperform with a $21.50 target in February, and BTIG reiterated Buy at $23. The consensus rating is buy, with five analysts in bullish-or-outperform territory against two holds. The bull case rests on recovering commercial real estate origination volumes and BXMT's access to Blackstone's deal flow. The bear case centres on book value erosion from near-term loan delays and the sensitivity of a floating-rate portfolio to credit stress in commercial property.
Institutional ownership is broadly stable. BlackRock holds 14.2% and Vanguard holds 9.9%, with both adding modestly in Q1. Blackstone itself retains a 5.4% stake as of December. Baron Capital added 304,000 shares in Q4 and Norges Bank added 213,000. Insider activity is modest and routine — small quarterly sells from the President and CFO, nothing in excess of $32,000 in a single transaction, all carrying the lowest significance scores. There is no insider signal worth trading around here.
The next scheduled earnings event lands on July 22nd. The only recent earnings reaction on record — the April 22nd print — resulted in a fractional 0.2% down move. With the stock now back at book value and the JP Morgan upgrade fresh, what to watch is whether the short cover continues or stalls: any reversal in SI back above 6% of float, combined with a PCR re-inflation toward the March highs, would mark a re-engagement of the bears that this week's data suggests have largely stepped aside.
See the live data behind this article on ORTEX.
Open BXMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
